Cargando…
Drug Candidates for Autoimmune Diseases
Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established dr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143092/ https://www.ncbi.nlm.nih.gov/pubmed/35631330 http://dx.doi.org/10.3390/ph15050503 |
_version_ | 1784715720511193088 |
---|---|
author | Saurin, Sabrina Meineck, Myriam Erkel, Gerhard Opatz, Till Weinmann-Menke, Julia Pautz, Andrea |
author_facet | Saurin, Sabrina Meineck, Myriam Erkel, Gerhard Opatz, Till Weinmann-Menke, Julia Pautz, Andrea |
author_sort | Saurin, Sabrina |
collection | PubMed |
description | Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs. |
format | Online Article Text |
id | pubmed-9143092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91430922022-05-29 Drug Candidates for Autoimmune Diseases Saurin, Sabrina Meineck, Myriam Erkel, Gerhard Opatz, Till Weinmann-Menke, Julia Pautz, Andrea Pharmaceuticals (Basel) Review Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs. MDPI 2022-04-20 /pmc/articles/PMC9143092/ /pubmed/35631330 http://dx.doi.org/10.3390/ph15050503 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Saurin, Sabrina Meineck, Myriam Erkel, Gerhard Opatz, Till Weinmann-Menke, Julia Pautz, Andrea Drug Candidates for Autoimmune Diseases |
title | Drug Candidates for Autoimmune Diseases |
title_full | Drug Candidates for Autoimmune Diseases |
title_fullStr | Drug Candidates for Autoimmune Diseases |
title_full_unstemmed | Drug Candidates for Autoimmune Diseases |
title_short | Drug Candidates for Autoimmune Diseases |
title_sort | drug candidates for autoimmune diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143092/ https://www.ncbi.nlm.nih.gov/pubmed/35631330 http://dx.doi.org/10.3390/ph15050503 |
work_keys_str_mv | AT saurinsabrina drugcandidatesforautoimmunediseases AT meineckmyriam drugcandidatesforautoimmunediseases AT erkelgerhard drugcandidatesforautoimmunediseases AT opatztill drugcandidatesforautoimmunediseases AT weinmannmenkejulia drugcandidatesforautoimmunediseases AT pautzandrea drugcandidatesforautoimmunediseases |